ALN-TTR02

Known as: Anti-Transthyretin siRNA ALN-TTR02, RNAi Therapeutic-targeting Transthyretin ALN-TTR02 
A lipid nanoparticle (LNP)-based formulation consisting of small-interfering RNAs (siRNAs) directed against transthyretin (TTR) encapsulated in… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2017
01220122017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2015
2015
BACKGROUND Transthyretin-mediated amyloidosis is an inherited, progressively debilitating disease caused by mutations in the… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Transthyretin amyloidosis is caused by the deposition of hepatocyte-derived transthyretin amyloid in peripheral nerves… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2012
2012
1155 Nature Biotechnology think that Alnylam delivery technologies, some of which were in-licensed from Tekmira, single it out as… (More)
Is this relevant?
2012
2012
1155 Nature Biotechnology think that Alnylam delivery technologies, some of which were in-licensed from Tekmira, single it out as… (More)
Is this relevant?